



CHOICESM
Health Plans

VNSNY CHOICE Total Step Therapy Requirements

Effective: 12/01/2020

AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
----------	--

AMLODIPINE ORAL SUSPENSION

Products Affected

Step 2:

- KATERZIA 1 MG/ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC AMLODIPINE TABLETS WITHIN THE PAST 120 DAYS.
-----------------	--

ANTIDEPRESSANTS

Products Affected

Step 2:

- FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK
- FETZIMA 20 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG
CAPSULE,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND VIIBRYD WITHIN THE PAST 365 DAYS.
----------	--

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR 1 OF THE FOLLOWING: BALSALAZIDE, FORMULARY VERSION OF MESALAMINE 0.375G, MESALAMINE 400 MG CAP(DRTAB), MESALAMINE DR 800 MG TAB, OR FORMULARY VERSION OF MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS.
----------	--

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- CAPLYTA 42 MG CAPSULE
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE, OR LATUDA WITHIN THE PAST 365 DAYS.
-----------------	---

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE, ZIPRASIDONE, OR LATUDA), SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE), SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS
----------	--

ANTIULCER AGENTS

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE *gram capsule*
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE *omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule*
- *omeprazole 20 mg-sodium bicarbonate 1.1* *rabeprazole 20 mg tablet, delayed release*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS.
-----------------	---

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
-----------------	--

DPP-4 INHIBITORS

Products Affected

Step 2:

- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- TRADJENTA 5 MG TABLET

Details

Criteria	PRIOR CLAIM FOR JANUMET, JANUMET XR OR JANUVIA WITHIN THE PAST 120 DAYS
----------	---

DULOXETINE SPRINKLE

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE, DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE, DELAYED RELEASE

Details

Criteria	PRIOR CLAIM FOR FORMULARY GENERIC DULOXETINE CAPSULE WITHIN THE PAST 120 DAYS.
-----------------	--

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS.
-----------------	---

ENALAPRIL ORAL SOLUTION

Products Affected

Step 2:

- EPANED 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC ENALAPRIL ORAL WITHIN THE PAST 120 DAYS.
-----------------	--

FIDAXOMICIN

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS.
-----------------	---

GABAPENTIN SR

Products Affected

Step 2:

- GRALISE 300 MG
TABLET,EXTENDED RELEASE
- GRALISE 30-DAY STARTER PACK
300 MG (9)-600 MG (69) TABLET,EXT.
- GRALISE 600 MG
TABLET,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	---

INSULIN/GLP-1 ANALOG

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

Criteria	PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) LANTUS, LANTUS SOLOSTAR, OZEMPIC, TRESIBA, TRESIBA FLEXTOUCH, TOUJEO MAX SOLOSTAR, TOUJEO SOLOSTAR OR VICTOZA AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE), COMBO SULFONYLUREA-METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS.
----------	--

LISINOPRIL ORAL SOLUTION

Products Affected

Step 2:

- QBRELIS 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC LISINOPRIL WITHIN THE PAST 120 DAYS.
-----------------	--

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS
-----------------	---

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
-----------------	---

OPHTHALMIC ALLERGY - OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE DROPS,SUSPENSION
- BEPREVE 1.5 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR ONE OF THE FOLLOWING: OTC LORATADINE, OTC LORATADINE D, OTC CETIRIZINE, OTC CETIRIZINE D, OTC FEXOFENADINE, OTC FEXOFENADINE D, OTC LEVOCETIRIZINE, OTC GENERIC KETOTIFEN EYE DROPS 0.025%, LEVOCETIRIZINE, CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
-----------------	---

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- XELPROS 0.005 % EYE DROP
EMULSION

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF LATANOPROST (GENERIC XALATAN OR XALATAN) AND ONE OF THE FOLLOWING: ALPHAGAN P 0.1%, AZOPT, COMBIGAN, LUMIGAN 0.01%, SIMBRINZA, ROCKLATAN OR FORMULARY VERSION OF TRAVOPROST WITHIN THE PAST 365 DAYS.
-----------------	--

RENIN ANGIOTENSIN SYSTEM INHIBITORS

Products Affected

Step 2:

- TEKTURNA HCT 150 MG-12.5 MG TABLET
- TEKTURNA HCT 150 MG-25 MG TABLET
- TEKTURNA HCT 300 MG-12.5 MG TABLET
- TEKTURNA HCT 300 MG-25 MG TABLET

Details

Criteria	PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), GENERIC ARB COMBINATION OR GENERIC DIRECT RENIN INHIBITORS WITHIN THE PAST 120 DAYS.
-----------------	---

ROSUVASTATIN SPRINKLE

Products Affected

Step 2:

- EZALLOR SPRINKLE 10 MG CAPSULE
- EZALLOR SPRINKLE 20 MG CAPSULE
- EZALLOR SPRINKLE 40 MG CAPSULE
- EZALLOR SPRINKLE 5 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR GENERIC ROSUVASTATIN TABLET IN THE PAST 120 DAYS.
-----------------	---

SIMVASTATIN ORAL SUSPENSION

Products Affected

Step 2:

- FLOLIPID 20 MG/5 ML (4 MG/ML)
ORAL SUSPENSION
- FLOLIPID 40 MG/5 ML (8 MG/ML)
ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC SIMVASTATIN ORAL TABLETS WITHIN THE PAST 120 DAYS.
-----------------	--

SPIRONOLACTONE ORAL SUSPENSION

Products Affected

Step 2:

- CAROSPIR 25 MG/5 ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC SPIRONOLACTONE WITHIN THE PAST 120 DAYS.
-----------------	--

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS
----------	---

TACROLIMUS PACKETS

Products Affected

Step 2:

- PROGRAF 0.2 MG ORAL GRANULES IN PACKET
- PROGRAF 1 MG ORAL GRANULES IN PACKET

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF TACROLIMUS CAPSULES WITHIN THE PAST 120 DAYS
-----------------	---

INDEX

ALREX 0.2 % EYE DROPS,SUSPENSION.....	19	FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK.....	5
<i>aripiprazole 10 mg disintegrating tablet</i>	5	FANAPT 2 MG TABLET.....	5
<i>aripiprazole 15 mg disintegrating tablet</i>	5	FANAPT 4 MG TABLET.....	5
BEPREVE 1.5 % EYE DROPS.....	19	FANAPT 6 MG TABLET.....	5
CAPLYTA 42 MG CAPSULE.....	5	FANAPT 8 MG TABLET.....	5
CAROSPIR 25 MG/5 ML ORAL SUSPENSION.....	24	FETZIMA 120 MG CAPSULE,EXTENDED RELEASE.....	3
<i>clozapine 100 mg disintegrating tablet</i>	5	FETZIMA 20 MG (2)-40 MG (26) CAPSULE,EXTENDED RELEASE,24 HR,DOSE PACK.....	3
<i>clozapine 12.5 mg disintegrating tablet</i>	5	FETZIMA 20 MG CAPSULE,EXTENDED RELEASE.....	3
<i>clozapine 150 mg disintegrating tablet</i>	5	FETZIMA 40 MG CAPSULE,EXTENDED RELEASE.....	3
<i>clozapine 200 mg disintegrating tablet</i>	5	FETZIMA 80 MG CAPSULE,EXTENDED RELEASE.....	3
<i>clozapine 25 mg disintegrating tablet</i>	5	FLOLIPID 20 MG/5 ML (4 MG/ML) ORAL SUSPENSION.....	23
CYCLOPHOSPHAMIDE 25 MG CAPSULE.....	8	FLOLIPID 40 MG/5 ML (8 MG/ML) ORAL SUSPENSION.....	23
CYCLOPHOSPHAMIDE 50 MG CAPSULE.....	8	GRALISE 300 MG TABLET,EXTENDED RELEASE.....	14
DEXILANT 30 MG CAPSULE, DELAYED RELEASE.....	7	GRALISE 30-DAY STARTER PACK 300 MG (9)-600 MG (69) TABLET,EXT. RELEASE.....	14
DEXILANT 60 MG CAPSULE, DELAYED RELEASE.....	7	GRALISE 600 MG TABLET,EXTENDED RELEASE.....	14
DIFICID 200 MG TABLET.....	13	JENTADUETO 2.5 MG-1,000 MG TABLET.....	9
DIPENTUM 250 MG CAPSULE.....	4	JENTADUETO 2.5 MG-500 MG TABLET.....	9
DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE.....	10	JENTADUETO 2.5 MG-850 MG TABLET.....	9
DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE.....	10	JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	9
DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE.....	10	JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE.....	9
DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE.....	10	KATERZIA 1 MG/ML ORAL SUSPENSION.....	2
EPANED 1 MG/ML ORAL SOLUTION.....	12	<i>methotrexate sodium 2.5 mg tablet</i>	8
EZALLOR SPRINKLE 10 MG CAPSULE.....	22	<i>omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule</i>	7
EZALLOR SPRINKLE 20 MG CAPSULE.....	22		
EZALLOR SPRINKLE 40 MG CAPSULE.....	22		
EZALLOR SPRINKLE 5 MG CAPSULE.....	22		
FANAPT 1 MG TABLET.....	5		
FANAPT 10 MG TABLET.....	5		
FANAPT 12 MG TABLET.....	5		

<i>omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule</i>	7	SPRITAM 250 MG TABLET FOR ORAL SUSPENSION.....	25
OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE.....	1	SPRITAM 500 MG TABLET FOR ORAL SUSPENSION.....	25
OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE.....	1	SPRITAM 750 MG TABLET FOR ORAL SUSPENSION.....	25
OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE.....	1	TEKTURNA HCT 150 MG-12.5 MG TABLET.....	21
OSMOLEX ER 322 MG/DAY (129 MG AND 193 MG) TABLET, EXTENDED RELEASE.....	1	TEKTURNA HCT 150 MG-25 MG TABLET.....	21
PRADAXA 110 MG CAPSULE.....	18	TEKTURNA HCT 300 MG-12.5 MG TABLET.....	21
PRADAXA 150 MG CAPSULE.....	18	TEKTURNA HCT 300 MG-25 MG TABLET.....	21
PRADAXA 75 MG CAPSULE.....	18	TRADJENTA 5 MG TABLET.....	9
PROGRAF 0.2 MG ORAL GRANULES IN PACKET.....	26	VERSACLOZ 50 MG/ML ORAL SUSPENSION.....	5
PROGRAF 1 MG ORAL GRANULES IN PACKET.....	26	VIBERZI 100 MG TABLET.....	11
QBRELIS 1 MG/ML ORAL SOLUTION.....	16	VIBERZI 75 MG TABLET.....	11
<i>rabeprazole 20 mg tablet, delayed release</i>	7	VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK.....	5
REXULTI 0.25 MG TABLET.....	6	VRAYLAR 1.5 MG CAPSULE.....	5
REXULTI 0.5 MG TABLET.....	6	VRAYLAR 3 MG CAPSULE.....	5
REXULTI 1 MG TABLET.....	6	VRAYLAR 4.5 MG CAPSULE.....	5
REXULTI 2 MG TABLET.....	6	VRAYLAR 6 MG CAPSULE.....	5
REXULTI 3 MG TABLET.....	6	XATMEP 2.5 MG/ML ORAL SOLUTION.....	8
REXULTI 4 MG TABLET.....	6	XELPROS 0.005 % EYE DROP EMULSION.....	20
SAPHRIS 10 MG SUBLINGUAL TABLET.....	5	XHANCE 93 MCG/ACTUATION BREATH ACTIVATED AEROSOL.....	17
SAPHRIS 2.5 MG SUBLINGUAL TABLET.....	5	XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN.....	15
SAPHRIS 5 MG SUBLINGUAL TABLET.....	5		
SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	5		
SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	5		
SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH....	5		
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN.....	15		
SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION.....	25		